Clinical Scorecard: Effects of Disopyramide on Exercise Tolerance in Patients with Obstructive Hypertrophic Cardiomyopathy: Insights Beyond the Left Ventricular Outflow Tract Gradient

At a Glance

Key Highlights

• Disopyramide significantly reduces resting and peak exercise LVOT gradients in oHCM patients.
• Disopyramide decreases resting and peak heart rates and chronotropic response, leading to reduced peak oxygen consumption (pVO2).
• Quality of life and NYHA functional class show marginal improvement despite decreased exercise capacity.

Guideline-Based Recommendations

Diagnosis

• Use genetic testing and cardiovascular magnetic resonance to confirm sarcomeric mutations in oHCM.
• Assess symptom burden via NYHA class and quality of life questionnaires (e.g., MLHFQ).
• Perform combined transthoracic stress echocardiography and cardiopulmonary exercise testing (TTE-CPET) to evaluate LVOTO and exercise capacity.

Management

• First-line treatment includes cardioselective beta-blockers or non-dihydropyridine calcium channel blockers.
• Disopyramide is considered after failure of first-line agents and before septal reduction therapies.
• Disopyramide dosing typically 200-250 mg twice daily, often combined with beta-blockers.
• Consider newer agents like mavacamten for symptom relief and exercise capacity improvement, noting different mechanisms.

Monitoring & Follow-up

• Monitor LVOT gradients at rest and peak exercise via echocardiography.
• Assess heart rate response and chronotropic reserve during exercise testing.
• Evaluate functional capacity (pVO2) and quality of life periodically.
• Watch for changes in ejection fraction and diastolic function.

Risks

• Disopyramide may reduce peak exercise capacity due to chronotropic insufficiency.
• Potential negative inotropic effects require monitoring of left ventricular function.
• Long-term mortality impact of disopyramide-induced pVO2 reduction is unknown but historical data suggest comparable outcomes to other treatments.

Patient & Prescribing Data

Adults with obstructive hypertrophic cardiomyopathy carrying sarcomeric mutations and persistent symptoms despite first-line therapy

Disopyramide reduces LVOTO and heart rate but decreases exercise capacity; used mainly in combination with beta-blockers; marginal quality of life improvement observed

Clinical Best Practices

• Confirm diagnosis with genetic and imaging studies before initiating disopyramide.
• Use TTE-CPET to objectively assess treatment effects on LVOTO and exercise tolerance.
• Start disopyramide at controlled release doses of 200-250 mg twice daily alongside beta-blockers.
• Monitor heart rate and exercise capacity to detect chronotropic insufficiency.
• Balance symptom relief and LVOTO reduction against potential decreases in peak oxygen consumption.
• Consider alternative therapies like mavacamten for patients needing improved exercise capacity.

References

• 2020 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy
• EXPLORER-HCM Trial on mavacamten in obstructive hypertrophic cardiomyopathy
• Disopyramide use in obstructive hypertrophic cardiomyopathy: historical cohort studies